Skip to Content

Posts tagged with "Clinical Trials"

  • Alzheimer's Disease

    Vivek Ramaswamy’s Plans

    I last wrote about Vivek Ramaswamy in the context of his first company (Axovant). That one went public on the hopes for a retread Alzheimer’s drug to work out in Phase III, and if that sounds a little iffy to you, then join a fairly large club. Alzheimer’s is truly the approach-avoidance conflict writ large: from… Read More
  • Cancer

    What Passes For Positive Data

    So can someone explain this one for me? Halozyme has a hyaluoronidase enzyme (PEGPH20) that they’re developing as a therapeutic agent. The idea is that it’s going to be an add-on with other cancer therapeutic combinations, and would increase the exposure of the tumor cells to the actual chemotherapies by breaking down hyaluronan (hyalur… Read More
  • Alzheimer's Disease

    Clinical Trials, Up and Very Much Down

    Lots of news at both ends of the scale today. At the bad end would be Arrowhead Pharma, who have been exploring therapeutic RNA interference. That’s a hard row to hoe, and nothing illustrates that better than their announcement that they’re dropping three clinical programs, pretty much all the advanced research that they have, because… Read More
  • Academia (vs. Industry)

    Vanderbilt Heads Into the Clinic for Alzheimer’s

    There’s an interesting experiment underway at Vanderbilt, where a team from the university is taking a possible Alzheimer’s candidate into clinical trials on their own. Now, you could come up with several headlines for this, along the lines of “Academic researchers in way over their heads”, or “Plucky professors make e… Read More
  • Cancer

    More Juno CAR-T Deaths

    Remember back in the summer when Juno Therapeutics disclosed three patient deaths in one of their CAR-T oncology trials and the trial was put on hold? And then the hold was lifted about ten minutes later? OK, three days, but by clinical death standards, that’s pretty fast. Perhaps too fast, because now there have been more… Read More
  • Alzheimer's Disease

    Eli Lilly’s Alzheimer’s Antibody Does Not Work

    After years of work and untold amounts of money, Eli Lilly’s Alzheimer’s antibody, solanezumab, does not work. It does not help Alzheimer’s patients. No matter how many times you run the Phase III trials, or in which patient populations, they do not get better. No matter how many hopeful press articles you might have seen… Read More
  • Cardiovascular Disease

    The Long Saga of Apo-A1 Milano

    It’s been six years since I titled a post “Remember Apo-A1 Milano?” If you go back even further, I wrote about the topic on this blog back in 2003 (!); scroll down to the November 11 post on that page. You can see from that one that the saga goes well back into the 1990s, but… Read More
  • Clinical Trials

    Wholesale Clinical Data Fabrication

    Here’s a disturbing analysis of a long series of clinical trials conducted by Yoshihiro Sato and co-workers in Japan. As described in this article at Stat, Sato’s research (focusing on drug effects on hip fracture)  has been coming under question for some time now. He published results on 33 (!) clinical trials between 1997 and… Read More
  • Alzheimer's Disease

    The Best Beta-Secretase Inhibitor Yet in Alzheimer’s

    Merck has published new results on their latest Alzheimer’s drug candidate, the beta-secretase inhibitor verubecestat (MK-8931). The paper in Science Translational Medicine is quite interesting, both for what it says and what it doesn’t (or can’t, yet). BACE inhibitors have had quite a time of it over the years. Coming up with a m… Read More
  • Clinical Trials

    Antibiotics Are Hard, Continued

    I wrote here about an ingenious synthetic effort into structurally diverse ketolide antibiotics, structures that need a lot of work to make them from the ground up. Well, I have one of those good-news/bad-news reports: it looks like synthetic work will definitely be needed in this area, because the latest clinical candidate in it has… Read More